CCL5 and breast cancer: Previous studies demonstrate that PKM2 could interact with p65/NF-κB and affect the expression of downstream target genes in breast cancer and hypoxic pancreatic tumors [23, 24], while CCL5 was proved to be a downstream target gene of the NF-κB pathway [25].